Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer By Ogkologos - December 19, 2025 109 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an updated analysis of the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Manipulating an Immune Cell May Make Radiation Therapy More Effective, Study... February 12, 2024 EMA Recommends Granting a Marketing Authorisation for Toripalimab August 21, 2024 ASCO20 Virtual Research Round Up Podcast: Central Nervous System Tumors and... September 3, 2020 The UK Government’s spending review: Time to invest in the future... October 20, 2020 Load more HOT NEWS Man Gives Up His First-Class Seat For 88-Year-Old Woman, Makes Her... Arsenic Trioxide in Combination with All-Trans Retinoic Acid for the Treatment... Can’t Sleep? Tips for Coping with Insomnia First Cancer TIL Therapy Gets FDA Approval for Advanced Melanoma
